Oral use of iron with vitamin C in hemodialyzed patients☆☆☆

Objective: To investigate if oral use of Sorbifer Durules (EGIS Pharmaceutical Ltd, Budapest, Hungary) (1 tablet/d) is adequate for the maintenance of serum iron and vitamin C in normal range during recombinant human erythropoietin treatment in hemodialyzed patients. One tablet of Sorbifer Durules contains 100 mg of Fe2+ and 60 mg of vitamin C. Design: Short-term, open-label clinical trial. Setting: Hemodialysis units. Patients: Twenty-four adult patients with end-stage renal disease on hemodialysis. Intervention: Four-week treatment period of Sorbifer Durules, preceded and followed by iron and vitamin C washout periods. Main outcome measure: Fasting predialysis serum samples were collected on days 0, 28, 56, and 84 to determine hematocrit, blood hemoglobin, serum iron, total iron-binding capacity, transferrin saturation, ferritin, vitamin C, and plasma oxalate. Results: Four-week treatment in hemodialyzed patients by Sorbifer Durules led to significant increase of hematocrit, blood hemoglobin, serum iron and vitamin C. This treatment did not influence the level of plasma oxalate. Conclusion: Oral dose of one tablet of Sorbifer Durules per day is adequate for the maintenance of serum iron in normal range during recombinant human erythropoietin treatment in hemodialyzed patients. This treatment simultaneously prevented the development of serum vitamin C deficiency and did not lead to further increase of plasma oxalate in these patients. © 2003 by the National Kidney Foundation, Inc.